Skip to main content
An official website of the United States government
Grant Details

Grant Number: 4R01CA160233-05 Interpret this number
Primary Investigator: Finkelstein, Dianne
Organization: Massachusetts General Hospital
Project Title: Rare Cancer Genetics Registry
Fiscal Year: 2016


DESCRIPTION (provided by applicant): Taken as an aggregate, rare cancers (those affecting fewer than 200,000 people in the US according to the Orphan Disease Act definition) account for 27% of the US cancer diagnoses and 25% of cancer mortality. However, while new therapies have changed the way some common cancers are treated, there has been little advance in the treatment of most rare cancers and research directed at these diseases is sparse. The main goal of this proposal is to expand the infrastructure and launch a research program for the Rare Cancer Genetics Registry (RCGR), a project that was funded by an NIH Challenge grant in 2009 to "promote research into the causes and treatment of these diseases". Currently, the RCGR is a registry with over 500 participants and consists of a coordinating center at Massachusetts General Hospital, five academic clinical recruiting sites, and an academic medical informatics site. This proposal plans to expand the registry by 600 participants with very rare (incidence below 5,000/year in the US) and understudied cancers. Registrants will be recruited at 5 academic clinical sites and from registries of existing foundations during the 5 years of the grant. Diagnoses of chordoma, uveal melanoma, Merkel cell carcinoma, vulvar cancer, and adenoid cystic carcinoma will be the focus of recruitment, chosen due to preliminary results and feasibility of recruitment during the 5-year project period. Tumor tissue and DNA will be obtained, along with chart-abstracted data on diagnosis, treatment, response and recurrence. Registrants will be consented for re-contact to participate in future studies. A new research program will be launched, aimed at 1) characterizing the genetic profile of rare tumors that could inform the choice of therapeutic interventions, and 2) understanding the clinical, pathological, and therapeutic predictors of outcomes of response and recurrence and late effects in rare cancer patients. The tumor genotyping will be carried out using a state-of-the-art robotic technology that detects a set of mutations that arise in many common cancers, and for which potential targeted therapies are available or in development. The outcomes analysis will require sophisticated statistical methods that can deal with the small numbers of patients within each individual diagnosis by appropriately analyzing the aggregate of patients in the registry. This proposed project could provide resources that will be available to the wider research community and will serve cancer research for many years to come.


Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
Authors: Smart A.C. , Goyal L. , Horick N. , Petkovska N. , Zhu A.X. , Ferrone C.R. , Tanabe K.K. , Allen J.N. , Drapek L.C. , Qadan M. , et al. .
Source: Annals of surgical oncology, 2020 Apr; 27(4), p. 1122-1129.
EPub date: 2019-12-23.
PMID: 31873931
Related Citations

Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer.
Authors: Yerramilli D. , Drapek L. , Nipp R.D. , Horick N. , Moran S.M.C. , NoƩ B. , D'Arpino S.M. , Mitra D. , Hong T.S. , Ryan D.P. , et al. .
Source: Journal of gastrointestinal cancer, 2020 Mar; 51(1), p. 204-210.
PMID: 30980294
Related Citations

High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
Authors: Mitra D. , Horick N.K. , Brackett D.G. , Mouw K.W. , Hornick J.L. , Ferrone S. , Hong T.S. , Mamon H. , Clark J.W. , Parikh A.R. , et al. .
Source: The oncologist, 2019 Jun; 24(6), p. e275-e283.
EPub date: 2019-02-12.
PMID: 30755500
Related Citations

Are rare cancer survivors at elevated risk of subsequent new cancers?
Authors: Finkelstein D.M. , Horick N.K. , Ramchandani R. , Boyd K.L. , Rana H.Q. , Bychkovsky B.L. .
Source: BMC cancer, 2019-02-21; 19(1), p. 166.
EPub date: 2019-02-21.
PMID: 30791872
Related Citations

Physical symptoms in long-term survivors of rare cancer.
Authors: Horick N.K. , Muzikansky A. , Gutierrez H.L. , Boyd K.L. , Finkelstein D.M. .
Source: Journal of cancer survivorship : research and practice, 2018 Dec; 12(6), p. 835-842.
EPub date: 2018-10-12.
PMID: 30315392
Related Citations

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529.
Authors: Mitra D. , Hong T.S. , Horick N. , Rose B. , Drapek L.N. , Blaszkowsky L.S. , Allen J.N. , Kwak E.L. , Murphy J.E. , Clark J.W. , et al. .
Source: Advances in radiation oncology, 2017 Apr-Jun; 2(2), p. 110-117.
EPub date: 2017-02-06.
PMID: 28740921
Related Citations

Physical and psychological health in rare cancer survivors.
Authors: Horick N.K. , Manful A. , Lowery J. , Domchek S. , Moorman P. , Griffin C. , Visvanathan K. , Isaacs C. , Kinney A.Y. , Finkelstein D.M. .
Source: Journal of cancer survivorship : research and practice, 2017 Feb; 11(1), p. 158-165.
EPub date: 2016-10-19.
PMID: 27761785
Related Citations

Assessing survival benefit when treatment delays disease progression.
Authors: Schoenfeld D.A. , Finkelstein D.M. .
Source: Clinical trials (London, England), 2016 Jun; 13(3), p. 352-7.
EPub date: 2016-02-22.
PMID: 26908538
Related Citations

A joint test for progression and survival with interval-censored data from a cancer clinical trial.
Authors: Finkelstein D.M. , Schoenfeld D.A. .
Source: Statistics in medicine, 2014-05-30; 33(12), p. 1981-9.
EPub date: 2014-02-06.
PMID: 24500790
Related Citations

Back to Top